SSY Group Limited announced that the National Medical Products Administration of China has approved the registration of the Group’s Azilsartan Medoxomil Potassium as a bulk drug for market preparations.
According to the voluntary filing dated 21 May 2026, the antihypertensive active pharmaceutical ingredient is indicated for treating primary hypertension in adults. The registration authorisation allows the compound to be supplied for formulation and commercialisation within China.
The disclosure aims to update shareholders and potential investors on the Group’s product-development progress.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments